RecruitingNot ApplicableNCT06048796

Early Cessation of Sedation and TTM in Patients With a Favourable EEG After Cardiac Arrest

Early Cessation of Sedation and TTM in Patients With a Favourable EEG After Cardiac Arrest: a Feasibility and Safety Study


Sponsor

Medisch Spectrum Twente

Enrollment

40 participants

Start Date

Mar 12, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The objective of this study is to estimate the feasibility and safety of early weaning from ICU treatment in patients after cardiac arrest and an early (\< 12 h) favourable EEG pattern (indicating no or mild postanoxic encephalopathy).


Eligibility

Min Age: 18 Years

Inclusion Criteria6

  • Patients after cardiac arrest admitted to the ICU for treatment with sedation, TTM and mechanical ventilation.
  • Age 18 years or older.
  • Continuous EEG measurement started within 12 hours after cardiac arrest.
  • Favourable EEG pattern within 12 hours after arrest, defined as a continuous background pattern (NVN, 2019; Ruijter et al., 2019).
  • Possibility to stop sedative treatment within three hours after identification of a favourable EEG pattern.
  • Written informed consent (deferred).

Exclusion Criteria5

  • A known history of another medical condition with limited life expectancy (\<6 months).
  • Any progressive brain illness, such as a brain tumour or neurodegenerative disease.
  • Pre-admission Glasgow Outcome Scale Extended score of 4 or lower.
  • Reason other than neurological condition to continue sedation and/or ventilation.
  • Follow-up impossible due to logistic reasons.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHEREarly cessation of sedation and TTM

Early cessation of sedation and TTM, with subsequent weaning from mechanical ventilation if appropriate


Locations(2)

Rijnstate hospital

Arnhem, Gelderland, Netherlands

Medisch Spectrum Twente

Enschede, Overijssel, Netherlands

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06048796


Related Trials